Prediction of the Development of Hepato-Cellular-Carcinoma in Patients with Liver Cirrhosis by the Serial Determinations of Serum Alpha-L-fucosidase Activity.

Ishizuka, Hideo; Nakayama, T; Matsuoka, Satoshi; Gotoh, Iori; Ogawa, Masahiro; Suzuki, Kazutomo; Tanaka, Naohide; Tsubaki, K; Ohkubo, Hitoshi; Arakawa, Yasuyuki; Okano, Tadao

doi:10.2169/internalmedicine.38.927

Cited by 54 publications

(27 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A screening test should be able to identify early disease, not late disease. Other tests that have been reported as screening tests included the ratio of glycosylated AFP (L3 fraction) to total AFP, 128-134 alpha fucosidase 135,136 and glypican 3. 137,138 None of these has been adequately investigated and cannot be recommended as a screening test.…”

Section: Surveillance Testsmentioning

confidence: 99%

Management of hepatocellular carcinoma

2005

View full text Add to dashboard Cite

Section: Surveillance Testsmentioning

confidence: 99%

Management of hepatocellular carcinoma

2005

View full text Add to dashboard Cite

“…Its activity increases obviously in the serum of HCC patients (1 418.62 ± 575.76 nmol/mL per hour) compared with that in the serum of healthy adults (504.18 ± 121.88 nmol/mL per hour, P <0.05), patients with cirrhosis (831.25 ± 261.13 nmol/mL per hour), and patients with chronic hepatitis (717.71 ± 205.86 nmol/mL per hour) [23,24] . It has been reported that the sensitivity and specificity of AFU at the cut-off value of 870 nmol/(mL per h) are 81.7% and 70.7%, respectively, in contrast with 39.1% and 99.3% of AFP at the cut-off value of 400 ng/mL, and the simultaneous determination of both markers can improve the sensitivity to 82.6% [23] .…”

Section: Alpha-l-fucosidasementioning

confidence: 99%

“…This indicates that AFU could serve as a valuable supplementary to AFP in the detection. Furthermore, it has been indicated that HCC will develop within a few years in 82% of patients with liver cirrhosis, if their serum AFU activity exceeds 700 nmol/(mL per h), and the activity of AFU is already elevated in 85% of patients at least 6 months before the detection of HCC by ultrasonography [24] . Thus, it can be seen that AFU could be a good tumor marker in detecting HCC at the earlier period.…”

Section: Alpha-l-fucosidasementioning

confidence: 99%

Serum tumor markers for detection of hepatocellular carcinoma

Zhou¹

2006

WJG

308

259

View full text Add to dashboard Cite

Alpha-fetoprotein and alpha-fetoprotein-L3Alpha fetoprotein (AFP) is a fetal specific glycoprotein produced primarily by the fetal liver. Normally, its serum concentration falls rapidly after birth and its synthesis in adult life is repressed. However, greater than 70% of HCC patients have a high serum concentration of AFP because of the tumor excretion. Forty years after its discovery, serum AFP remains a most useful tumor marker in screening HCC patients. The serum concentration of 20 ng/mL is the most commonly used cut-off value to differentiate HCC patients from healthy adults in clinical researches. However, some investigations have showed that the cut-off value is fluctuant in different ethnic groups. REVIEW Serum tumor markers for detection of hepatocellular carcinoma AbstractHepatocellular carcinoma (HCC) is one of the most frequent malignant tumors and is the second most common cause of cancer death in China. Therefore, it is very important to detect this disease and the recurrence at its earlier period. Serum tumor markers, as the effective method for detecting hepatocellular carcinoma for a long time, could be divided into 4 categories: oncofetal antigens and glycoprotein antigens; enzymes and isoenzymes; genes; and cytokines. Serum alpha fetoprotein (AFP) is the most widely used tumor marker in detecting patients with hepatocellular carcinoma, and has been proven to have capability of prefiguring the prognosis. However, it has been indicated that AFP-L3 and DCP excel AFP in differentiating hepatocellular c a r c i n o m a f r o m n o n m a l i g n a n t h e p a t o p a t h y a n d detecting small hepatocellular carcinoma. Some tumor markers, such as human cervical cancer oncogene and human telomerase reverse transcriptase mRNA, have also been indicated to have higher accuracies than AFP. Furthermore, some other tumor markers, such as glypican-3, gamma-glutamyl transferase II, alpha-lfucosidase, transforming growth factor-beta1, tumorspecific growth factor, have been indicated to be available supplementaries to AFP in the detection. AFP mRNA has been shown to correlate with the metastasis and recurrence of HCC, and it may be the most useful marker to prefigure the prognosis. Some other markers, such as gamma-glutamyl transferase mRNA, vascular endothelial growth factor, and interleukin-8, could also be used as available prognostic indicators, and the simultaneous determination of AFP and these markers may detect the recurrence of HCC at its earlier period.

show abstract

“…Higher activities of the enzyme were detected in HCC patients [13,19,20]. Furthermore, the persistently elevated AFU level in patients with cirrhosis adds to the detection of HCC at an earlier stage [20] owing to elevated activity of AFU at least 6 months before the detection of HCC by ultrasonography in 85% of patients [13].…”

Section: Introductionmentioning

confidence: 99%

Serological Biomarkers of Hepatocellular Carcinoma in Egyptian Patients

et al. 2012

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma (HCC) is one of the most aggressive cancers worldwide. In Egypt, the disease is usually detected in an advanced stage at which no treatment may be effective including surgery. Early detection of the disease is thus an important goal allowing the patient to be treated before the enlargement of the tumor or its metastasis to distant organs. Tumor markers are serological agents which serum level may be useful in predicting the presence of the tumor at early stages. Alpha fetoprotein (AFP) which is the golden marker for HCC is of low sensitivity, therefore, additional markers such as alpha-L-fucosidase (AFU), transforming growth factors alpha and beta (TGF-α and TGF-β) and interleukin-8 (IL-8) are suggested to be simultaneously evaluated in order to enhance the detection of HCC. A total of 96 patients with different liver diseases such as HCC, hepatitis C virus (HCV), hepatitis B virus (HBV) and cirrhotic patients are included in this study. Sixteen healthy volunteers are used as a control group. In patients with HCC each of AFP, AFU, TGF-α and TGF-β recorded significantly higher levels than the other patient groups and controls. HCC patients recorded significantly lower level of IL-8 compared to the other patient groups but significantly higher than the control. For AFP, AFU, TGF-α, TGF-β and IL-8, at the optimal cut-off values (obtained from the receiver operating characteristic (ROC) curves), the calculated sensitivities are 46%, 72.97%, 67.56%, 54.05% and 83.8%, respectively. The simultaneous evaluation using all of the suggested markers resulted in increasing the sensitivity up to 100%. It thus recommended that, if patients with cirrhosis, as high risk patients, are subjected to regular examination using these markers in addition to AFP, HCC may be detected by 100% sensitivity in an early stage and as a consequence an effective treatment can be achieved.

show abstract

Prediction of the Development of Hepato-Cellular-Carcinoma in Patients with Liver Cirrhosis by the Serial Determinations of Serum Alpha-L-fucosidase Activity.

Cited by 54 publications

References 14 publications

Management of hepatocellular carcinoma

Management of hepatocellular carcinoma

Serum tumor markers for detection of hepatocellular carcinoma

Serological Biomarkers of Hepatocellular Carcinoma in Egyptian Patients

Contact Info

Product

Resources

About